(VIANEWS) – Shares of NANOBIOTIX (CAC 40: NANO.PA) slid by a staggering 15.03% to €2.04 at 14:05 EST on Wednesday, following the last session’s downward trend. CAC 40 is sliding 1.08% to €7,449.97, after two consecutive sessions in a row of losses. This seems, so far, an all-around down trend trading session today.
NANOBIOTIX’s last close was €2.40, 59.75% under its 52-week high of €5.95.
About NANOBIOTIX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -198.69%.
Yearly Top and Bottom Value
NANOBIOTIX’s stock is valued at €2.04 at 14:05 EST, way below its 52-week low of €3.10.
More news about NANOBIOTIX (NANO.PA).
